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ABSTRACT (Word count: 259) 
Background and Aims: Octreotide reduces splanchnic blood flow and is effective in 
gastrointestinal bleeding (GIB) due to portal hypertension. Monthly long-acting octreotide 
(OCT-LAR) with an efficacy and safety profile similar to subcutaneous daily administration, 
presents an attractive option for long-term therapy. We report our experience with OCT-
LAR for severe/recurrent GIB in children with portal hypertension secondary to chronic liver 
disease or portal vein thrombosis who were unresponsive to standard interventions.  
Patients and Methods: 9 patients, 7 males, who received OCT-LAR between 2000 and 
2009 were studied retrospectively (median age at first bleeding 21 months; range, 1 month-
14.5 yrs). The dose (2.5 to 20 mg intramuscularly monthly) was extrapolated from that used 
in adult acromegaly and neuroendocrine tumours (10-60 mg/month). Response to 
treatment was assessed by comparing number of bleeding events, hospital admissions for 
acute bleeding and number of blood units required during the year before and year after 
starting OCT-LAR.  
Results: OCT-LAR led to a reduction in the number of bleeding episodes in all children, 
and to cessation of bleeding in 7. Two children listed for transplantation because of severe 
GIB were removed from the list. No serious side effects immediately attributable to OCT-
LAR were observed. One child developed growth hormone deficiency and hypothyroidism 
during a prolonged period of treatment with subcutaneous octreotide before commencing 
OCT-LAR.  
Conclusion: OCT-LAR can control severe intractable recurrent GIB in children with portal 
hypertension. Prospective randomized controlled trials and pharmacokinetic studies are 
indicated to establish the optimum dose and length of treatment of OCT-LAR and to confirm 
its efficacy and long-term safety in children. 
4 
 
INTRODUCTION 
Portal hypertension and gastrointestinal bleeding (GIB) are major complications of 
chronic liver disease [1]. Oesophago-gastroduodenoscopy (OGD) and/or ileocolonoscopy 
can identify the source of bleeding in up to 95% of patients, allowing targeted treatment. [2]. 
When the source of bleeding is not obvious, presumably in the small bowel, the treatment 
options are limited. Consequences of persistent or recurrent bleeding in paediatric age 
include fatigue, poor school attendance/performance and depression, secondary to chronic 
anaemia.  Intractable bleeding necessitates multiple investigations, surgical interventions 
and even consideration for liver transplantation [3]. The associated mortality ranges from 
2.5%-20% [4]. Treatment options for occult bleeding are limited, giving relevance to 
empirical pharmacological approaches   [2,5-11]. 
Octreotide, the first somatostatin analogue introduced for clinical use, inhibits the release of 
growth hormone, glucagon, and insulin. Octreotide markedly reduces splanchnic blood flow 
and has a half-life 30-100-fold longer than somatostatin [12,13]. It has a high affinity only to 
somatostatin receptors subtype 2 (sst2) and subtype 5 [14]. sst2 is largely expressed in 
neuroendocrine and non-neuroendocrine cells of the human gastrointestinal tissue [15]. 
Octreotide is licensed for symptomatic control and reduction of growth hormone and 
somatomedin C plasma levels in patients with acromegaly and for the relief of symptoms 
associated with functional gastroenteropancreatic tumors (GEP tumors) in adult patients 
[12]. In children, octreotide has been used on an unlicensed basis for treatment of 
hyperinsulinaemia, secretory diarrhoea, pancreatitis, chylothorax and acute GIB either as a 
continuous infusion or three times daily subcutaneous injection [16-19]. The long acting 
(OCT-LAR) formulation of octreotide can be administered once a month with similar efficacy 
and safety profile to subcutaneous daily administration [20,21,22]. Following a single 
intramuscular injection, OCT-LAR concentrations reach a plateau at day 14 and remain 
relatively constant for the following 3-4 weeks in adults [23]. OCT-LAR therefore represents 
an attractive option for long-term therapy of GIB. Use of OCT-LAR in children is limited by 
lack of pharmacokinetic data, clinical experience, and several described adverse events, 
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including nausea, abdominal cramps, diarrhoea, fat malabsorption, reduced glucose 
tolerance and development of gallstones [20-24]. Moreover, octreotide has the potential to 
interfere with endocrine mechanisms, a side effect particularly significant in the paediatric 
population. We report our experience on the use of OCT-LAR in treating severe GIB in 
children with portal hypertension secondary to chronic liver disease or portal vein 
thrombosis not responding to multiple conventional interventions, including variceal 
sclerotherapy or banding and intravenous or subcutaneous octreotide.  
 
PATIENTS AND METHODS 
The Paediatric Liver Service at King’s College Hospital, London, UK is a tertiary 
referral centre where some 500 new children with acute or chronic liver disorders are 
referred each year. From our database we have identified and reviewed retrospectively the 
clinical and laboratory data of all children in whom OCT-LAR, commercially available since 
1998, has been used. Indications for OCT-LAR therapy were persistent GIB of unknown 
origin or resistant variceal bleeding previously treated with banding or sclerotherapy, with no 
or only partial response to intravenous octreotide. 
Obscure GIB was defined as bleeding in the absence of an obvious cause; occult 
GIB as laboratory evidence of blood in the stools without macroscopic change in their 
appearance [10]. Cause of bleeding were investigated using a combination of tests, as 
detailed in the result section. 
In the patients in whom oesophageal and/or gastric varices were identified, banding 
or sclerotherapy were performed. All patients with acute haemorrhage unresolved by 
sclerotherapy and banding were treated with a standard continuous intravenous octreotide 
infusion (50 mcg per hour, irrespective of the weight), slowly weaned down over 24-48 hrs 
after bleeding stopped [11]. If persistent re-bleeding occurred after at least 4 
sclerotherapy/banding sessions, necessitating frequent hospital admissions and numerous 
transfusions, the children were considered for treatment with OCT-LAR.  
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OCT-LAR was administered intramuscularly at a dose of 2.5 to 20 mg monthly. The 
initial dose was extrapolated from adult data for the treatment of acromegaly and 
neuroendocrine tumours, i.e. 20-60 mg every 4 weeks [25][26] . The paediatric dose was 
calculated as percentage of an average adult weight rounded to the closest 2.5 mg for ease 
of administration (not exceeding 20 mg). Blood transfusion was given when haemoglobin 
values fell below 8 g/dl or when acute clinical bleeding occurred (1 transfusion unit = 250 ml 
blood). Response to treatment was assessed using the number of bleeding events, hospital 
admissions for acute bleeding episodes and the number of blood units required during the 
year before and the year after initiation of therapy. Adverse effects during therapy were 
recorded retrospectively from the clinical notes. 
 
STATISTICAL METHODS 
    
The primary end point was to determine the number of recurrent bleeding episodes in 
the 12 months after treatment with OCT-LAR compared to the previous 12 months. 
Secondary end points included the effect of OCT- LAR on the number of blood units 
transfused, on the number of hospital admissions and on the length of hospital stay. 
Continuous variables are described by means of median values and ranges. Wilcoxon 
signed rank test was used to compare the number of bleeding events, number of 
transfusions, number of hospital admissions and number of days in hospital 1 year before 
and 1 year after OCT-LAR therapy. A P value <0.05 was considered significant.  
 
RESULTS  
Nine patients, 7 males, who had received OCT-LAR from 2000-2009 were identified and 
studied. The median age at first bleeding was 21 months (range, 1 month-14.5 yrs). Their 
diagnoses, treatment and outcome are summarized in Table 1. All patients had a history of 
intermittent acute GIB (haematemesis, melaena, haematochezia), leading to severe 
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anaemia requiring repeated blood transfusions. The underlying disease was biliary atresia in 
7 (78%) children, 4 (57%) of whom had a successful (e.g. leading to normalization of serum 
bilirubin) Kasai portoenterostomy (KPE), while the remaining 3 (43%) with persistent 
jaundice eventually required liver transplantation. Two of them developed portal 
hypertension as a consequence of portal vein thrombosis after liver transplant. 
One child had Klippel-Trénaunay-Weber syndrome and thrombosis of the portal vein, while 
another had diffuse gastrointestinal arterio-venous malformation complicated by 
arterialisation of the portal vein system and subsequently required partial hepatectomy. 
All patients had portal hypertension characterised by recurrent bleeding and 
thrombocytopenia with 7 patients reported to have spenomegaly. The remaining two, 
patients 5 and 8 with no splenomegaly had polysplenia as part of their biliary atresia-splenic 
malformation (BASM) syndrome.The universal presenting features were chronic anaemia (9 
patients, 100%) and melaena (9 patients, 100%), while haematochezia was present in 7 
(78%) and haematemesis in 6 (67%) children. There was no personal or family history of 
haemorrhagic disorders. Patient 4 was on long-term warfarin therapy due to the underlying 
Klippel-Trénaunay-Weber syndrome and chronic disseminated intravascular coagulopathy 
[27-29]; patient 8 was temporarily treated with aspirin (8 mg/kg) due to a thrombus in the 
inferior vena cava and transiently high platelet count.  After 3-month treatment aspirin 
therapy was discontinued due to anaemia, faecal occult blood, and thrombocytopenia which 
continued following the withdrawal. Three patients (patients 6, 7 and 9) were on 
maintenance propranolol therapy (0.5-1 mg/Kg/day) both before and after treatment with 
OCT-LAR. 
The tests performed to investigate the cause of bleeding included: oesophagous 
gastro duodenoscopy (OGD) in 9 (100%) patients, colonoscopy in 6 (67%), video capsule 
endoscopy in 4 (44%), angiography in 5 (56%), explorative laparotomy in 5 (56%), 
technetium-99m-labelled erythrocytes scintigraphy in 2 (22%), abdominal computerised 
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tomography (CT) scan in 2 (22%), abdominal magnetic resonance imaging (MRI) in 2 (22%), 
and barium meal and follow through  in 1 (11%). 
A bleeding site was found in 5 cases (56%) (Table 1). Patient 1 had a vascular 
lesion, bleeding profusely, above the recto-sigmoid junction. This was detected by 
colonoscopy and treated by electro-coagulation. Grade 3 oesophageal varices and grade 2 
gastric varices were detected by OGD in patient 4 and the oesophageal varices were 
subsequently banded. Teleangiectasiae were also found by colonoscopy in the low caecum 
in this patient, but could not be treated. In patient 5 multiple bleeding lesions in the Roux-
loop with fresh blood and clots were detected during laparotomy, and in patient 6 multiple 
friable haemorrhagic polypoid lesions were found in the proximal part of duodenum which 
could not be treated. In patient 8 grade 3 oesophageal varices were detected by OGD and 
treated with sclerotherapy. In all cases where the bleeding sites were treated, rebleeding 
occurred after the procedures with no reduction in the rate of episodes and blood transfusion 
requirements. In the remaining 4 children (44%) no active bleeding site was found, though 
non-bleeding oesophageal varices were seen in patient 2 during OGD and CT scans 
suggested presence of Roux loop varices in patients 3, 7 and 9.  
The median age at commencement of therapy with OCT LAR was 71 months 
(range, 3-190). The median number of injections received was 13 (range, 1-90). Three 
patients received only one dose. The median dose was 0.36 mg/kg (range, 0.16-0.95). The 
patients have been followed up for a median of 62 months (range, 12-111) from initiation of 
the therapy (Table 1).  
Three patients were excluded from statistical analysis: Patient 1 because he had 
received subcutaneous octreotide immediately prior to starting OCT-LAR, patient 5 as he 
was only 3 months old at initiation of therapy and patient 8 because his follow-up was 
shorter than 12 months. Patient 8 had received a single dose of OCT-LAR with no further 
bleeding, but underwent transplantation after 4 weeks. In the remaining 6 patients the 
median number of injection was 12.5 (range, 1-36), the median dose received for these 6 
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patients was 0.38mg/kg (range, 0.29-0.95), and the median follow up was 65.5 months 
(range, 5-100) from the initiation of treatment. In these 6 patients all parameters were 
analysed for the year before and the year after the initiation of therapy. The overall number 
of bleeding events decreased in all children after OCT-LAR therapy (Table 2) Two  patients 
(Patients 3 and 6) stopped bleeding immediately after the first dose of OCT-LAR.  However, 
Patient 3, whose OCT-LAR treatment was discontinued after 10 months, had a single bleed 
7 months later. Patient 6 who had no reported bleeding episodes for 18 months after the 
first dose of OCT-LAR, started bleeding again, though the severity and frequency of the 
bleeding episodes were markedly reduced when compared to before receiving OCT-LAR. 
Patient 2 had a single dose of OCT-LAR with a conspicuous reduction in bleeding episodes 
and no further OCT-LAR was administered.  The remaining 3 patients (Patients 4, 7 and 9) 
stopped bleeding after 3, 7, and 2 injections (Table 1). The median number of blood 
transfusion units required per patient as well as the number of hospital admissions 
decreased in all children (Table 2). A reduction in the median length of hospital stay was 
also observed (Table 2). Five out of eight patients received monthly OCT-LAR injections for 
>6 months.  
Excluding Patient 1, who had already stopped bleeding while on subcutaneous 
octreotide prior to commencement of OCT-LAR, bleeding ceased in 7 of the remaining 8 
patients: in 4 after the first injection of OCT-LAR (two of whom received only one dose) and 
in 3 after a median of 3 doses (range, 2-7) (Table 1). 
OCT-LAR was well tolerated in all patients. There were no reports of tachyphylactic 
reactions, gallstones and liver or pancreatic disturbance (25). Apart from patient 1 (see 
below), no endocrine abnormalities were noted.  
Patient 1 received subcutaneous octreotide (9.7 mg/kg/day in three divided doses) 
for 11 months before starting OCT-LA. As this was our first use of prophylactic 
subcutaneous octreotide, the dose was derived from the hyperinsulinaemia treatment (up to 
40 mcg/kg/day). Episodes of bleeding reduced from 219 over 12 months prior to sub 
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cutaneous octreotide to 14 in the first seven months of subcutaneous therapy. 
Subsequently the bleeding stopped. OCT-LAR was started 11 months after subcutaneous 
octreotide therapy commenced and continues to the present day. Bleeding has never 
resumed and after 3 years the frequency of OCT-LAR was reduced to every six weeks. The 
family remains reluctant to stop therapy due to their concerns that GIB may re-occur. Whilst 
on subcutaneous octreotide, Patient 1 developed diarrhoea and abdominal bloating, which 
resolved soon after initiation of OCT-LAR. He was also diagnosed with growth hormone 
deficiency during the first year he was receiving daily subcutaneous octreotide therapy. At 
the age of 14 years, whilst on subcutaneous octreotide, a growth hormone release hormone 
test showed no growth hormone response, and his height velocity had reduced markedly 
from 8.2 cm/year to 3.1 cm/year. Testicular volumes were appropriate for the pubertal 
growth spurt. Due to the reduced height velocity, the decision was made to commence 
somatropin therapy for the remaining growth years. Fourteen months after starting 
subcutaneous octreotide serum T4 level was at the lower limit of normal at 10.1 pmol/L 
(normal range, 10-23 pmol/L), leading to the initiation of levothyroxine supplements (100 
mcg/day). The patient’s growth and development has subsequently been normal (along the 
50th centile for height and 75th for weight throughout his adolescence). 
At last follow up, 7 patients were alive with no evidence of GIB: 3 on regular OCT-
LAR treatment (Patient 1, 7 and 9), 1 on intermittent (before long haul flights) treatment 
(Patients 3), 2 off treatment (Patient 2, re-transplanted for chronic rejection 6 years after the 
first transplant and Patient 4). Patient 6 has minor GIB episodes triggered by sharp food 
treated with OCT-LAR (about 3 injections/year). One patient had a liver transplant 
performed 4 weeks after starting OCT-LAR (Patient 8). Two patients (Patients 7 and 9), 
who had been listed for re-transplant and transplant, respectively, because of severe 
persistent GIB, were removed from the transplant list, as they stopped bleeding on OCT-
LAR. One patient (Patient 5) died of an intracranial haemorrhage of unknown 14 months 
after a single dose of OCT-LAR.  
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DISCUSSION  
Our data provide novel evidence that OCT-LAR is effective, with no apparent 
serious adverse effects, in controlling severe GIB in children with advanced portal 
hypertension, in whom conventional endoscopic and medical treatments fail. Present 
international guidelines also include transjugular intrahepatic portosystemic shunting (TIPS) 
as a potential management option with considerable technical limitations in infants and 
small children [30], but in our centre TIPS is considered only as a bridge to liver 
transplantation.  
Continuous intravenous infusion of somatostatin analogues remains a standard 
therapy for acute GIB episodes in both adult and paediatric patients with portal 
hypertension [11,15-19]. Subcutaneous octreotide therapy is effective in preventing 
recurrent bleeding episodes in adults [31-34], but the requirement for three times daily 
administration renders it impractical for long term prophylaxis, particularly in children. 
Moreover, fluctuating octreotide serum levels have been reported with subcutaneous 
therapy [33]. In adults, OCT–LAR administered on a monthly basis has similar efficacy to 
subcutaneous therapy, and results in sustained blood levels [21,32,33]. These features of 
OCT-LAR prompted us to use it in children with refractory GI bleeding, despite the lack of 
paediatric studies for this indication. 
In paediatrics, OCT-LAR has been used anecdotally for the treatment of Prader-Willi 
syndrome, but with no firm dose recommendations [24]. The dose we used was extrapolated 
down for weight from that recommended for the treatment of acromegaly and 
neuroendocrine tumours in adults [median dose 0.36mg/kg/month (range 0.16-
0.95mg/kg/month)], corresponding to an adult dose of 23mg/month (range 10-60mg/month) 
[12,26]. One child received a dose of 20mg, 0.95mg/kg/month equivalent to 60mg in an adult 
patient. This high dose, similar to that employed in some patients with neuroendocrine 
tumours [26], was chosen due to the severity of his symptoms at the time of treatment 
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initiation. The dose was not proportionally increased throughout his childhood as his 
symptoms remained well controlled; his current dose of 20mg is equivalent to 0.6mg/kg.   
It is possible that OCT LAR doses lower than those used might have been equally 
effective, as in few adults in whom OCT-LAR has been employed for gastrointestinal 
bleeding [35-38], both 20 mg and 10 mg monthly doses were reported to be effective [35-
38]. A randomized controlled study of eighteen adult cirrhotic patients with portal 
hypertension showed a decrease of the hepatic venous pressure gradient (HVPG) in the 
treated arm, but not in the placebo arm using OCT-LAR at a dose of 20 mg monthly for a 3 
month period [34]. Though a similar proportion of treated and untreated patients (70% and 
62% of octreotide and placebo treated patients, respectively) were taking β-blockers, it is 
possible that combined treatment with OCT-LAR and propranolol may have had an influence 
on the HVPG. In our study only 3 patients were taking propranolol at low doses during the 
year before and the year after starting OCT-LAR. As we did not measure HVPG we cannot 
comment on the possible cumulative effect of the β-blocker.  In another study, on the 
assumption that the effect of octreotide on the GI tract - mediated by ss2A receptor subtypes 
– may be achieved by doses lower than those required to inhibit tumour growth, Scaglione et 
al. assessed the effectiveness of 10 mg/month OCT-LAR in controlling chronic bleeding from 
gastrointestinal angiodysplasias in 13 adult patients [37]. During treatment a decrease in the 
number of transfusions as well as in the number and length of hospital admissions was 
noted; in three patients who did not respond to 10 mg/month the dose was increased to 20 
mg/month with no benefit. 
 The present study shows a significant reduction in the number of bleeding episodes 
in the year following the start of OCT-LAR treatment in all children, and, in addition, it 
shows complete cessation of bleeding in seven of them. Most importantly, two children who 
were listed for liver transplantation because of the severity of their GIB were removed from 
the list and remain well with no further episodes of bleeding several months after starting 
OCT-LAR treatment.  
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As our study was not randomized and there was a great variation in the frequency 
and number of injections received by our patients, it is difficult to draw conclusions on how 
many doses are required to control bleeding. Among the eight patients who stopped 
bleeding, four did so after the first injection of OCT-LAR, two of whom received only one 
dose (one died and one was transplanted); one patient had already stopped bleeding on 
subcutaneous octreotide therapy prior to commencement of OCT-LAR; the remaining three 
stopped bleeding after a median of 3 (range, 2-7) injections. For Patient 2, who had a 
marked reduction of bleeding episodes after a single dose, the role of OCT-LAR remains 
speculative. We did not observe serious side effects immediately attributable to OCT-LAR 
treatment. Patient 5 died 11 months after a single dose of OCT-LAR, but, given the time 
interval between receiving OCT-LAR and death of intracranial haemorrhage, it is unlikely 
that the use of octreotide has contributed to his death. Patient 1 developed growth hormone 
deficiency and hypothyroidism during a prolonged period of treatment with a relatively high 
dose of subcutaneous octreotide (10 mcg/kg/day compared to 0.16 mcg/kg monthly whilst 
receiving OCT-LAR) before starting OCT-LAR. As no further bleeding episodes occurred in 
the following 8 years of OCT-LAR therapy, it is possible that, had OCT-LAR been used 
initially, he would have stopped bleeding without developing adverse effects, as we 
observed in the remaining 8 patients.  
In contrast with the lack of side effects attributable to OCT-LAR in our series, a 
recent paper aiming at investigating the safety and efficacy of OCT-LAR in adult patients 
with Child Pugh Class A or B cirrhosis, no history of GI bleeding and small oesophageal 
varices, reports adverse events characterized by abdominal cramps, diarrhoea and 
hypoglycaemia in four out of ten patients treated with a dose of 30mg/month, while no 
serious side effects were detected in patients treated with 10mg/month.[39] In the same 
multicentre study no haemodynamic benefit with either OCT-LAR dose was demonstrated 
by measuring HVPG, but the authors emphasise that the quality of the HVPG tracings 
across centres was variable making interpretation difficult. Though both the end-points and 
the patient characteristics in that study are different from those in our report, it is intriguing 
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that  no abdominal adverse effects or hypoglycaemia were reported in any of our children. It 
is important to note, however, that only three of our nine patients received an equivalent 
OCT-LAR dose ≥30mg/month if extrapolated. We suggest, therefore, that caution should be 
exercised before using doses at the higher end of the spectrum. 
Due to its small size and its retrospective nature, this study is unable to recommend 
an optimal length of OCT-LAR treatment vis a vis the recurrence of bleeding and the risk of 
side effects, but an empirical approach with monitoring of the thyroid function and growth 
velocity appears to be prudent.   
In conclusion, this pilot experience indicates that OCT-LAR may be effective in 
controlling severe recurrent GIB not amenable to conventional endoscopic treatment in 
children with portal hypertension caused by chronic liver disease and gastrointestinal 
vascular malformations. This therapy is less invasive than daily subcutaneous octreotide 
injections, reducing compliance issues. Adverse effects are uncommon but regular 
endocrine assessment, particularly in adolescent patients, is recommended. 
Pharmacokinetic studies and prospective randomized controlled trials are necessary in 
order to establish the optimum dose and length of treatment of OCT-LAR and to confirm its 
efficacy and long term safety in treating severe GIB in children. 
 
Table 1 
 
TABLE 1. PATIENT CHARACTERISTICS, DOSAGE OF LONG-ACTING OCTREOTIDE AND OUTCOME 
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Pt No. 
(Sex) 
Diagnosis Age at 
first 
bleeding 
(months) 
Source of 
bleeding 
Age at 
first dose 
(months) 
Dose 
(mg) 
Dose 
(mg/kg) 
No of 
doses 
Follow up 
post 
therapy 
(No. of 
months) 
Clinical details and outcome 
 
1 
(M) 
 
BA 
successful 
Kasai 
2.5 Throughout the 
gut 
180 10 0.16 90 111 Subcutaneous octreotide for 11 months 
before OCT-LAR. 
Monthly OCT-LAR for 3 years, then 
 6-weekly to date.  
No further GIB. Growth hormone 
deficiency, hypothyroidism. 
2 
(M) 
 
BA, failed 
Kasai 
PVT  post-LT 
12 Oesophageal 
varices  
29 5 0.36 1 80 LT at 10 months of age. PVT 18 months 
post LT.   
Marked reduction of bleeding episodes 
after a single dose of OCT-LAR. PTLD 
then chronic rejection. Re LT at 7 years 
of age 
3 
(M) 
 
BA 
successful 
Kasai 
 
21 Roux loop 
varices 
35 5 0.35 15 69 No GIB during a 10-month course of  
monthly OCT-LAR.  
GIB 7 months after stopping OCT-LAR, 
following a long haul flight.   
No further GIB with OCT-LAR 
administered 14 days before long haul 
flights (>5 hours) 
4 
(F) 
 
KTW 
syndrome 
PVT 
175 Grade 3 
oesophageal 
varices  grade 
2 gastric 
varices, 
Telangiectasia 
in the lower 
caecum 
190 20 0.29 15 62 Long-term Warfarin treatment. PVT 
diagnosed at 14 years.  
Severe GIB aged 14-16 years.  
Only one GIB episode during 15 doses 
of monthly OCT-LAR. 
One episode 2 months after cessation 
of therapy. No further GIB  
5 
(M) 
 
BA  
failed Kasai 
1 Roux loop 3 2.5 0.46 1 14 Died of intracranial haemorrhage aged 
17 months, no further GIB. Post mortem 
refused by family. 
6 
(M) 
 
Liver + gut 
AVM 
Portal vein 
arterialization 
60 Oesphageal, 
gastric and 
duodenal 
varices 
138 20 0.95 36 100 Microcephaly + developmental delay. 
Partial hepatectomy aged 3 years; 
banding of oesophageal varices aged 
10 years.  Propranolol 1mg/kg/day 
Monthly OCT-LAR from  11-17 years. 
No GIB after the first dose for 18 
months and then a marked reduction in 
the number and severity of episodes. 
From age 17, minor GIB episodes 
triggered by sharp food treated with 
OCT-LAR about 3 times/year. 
7 
(F) 
 
BA, failed 
Kasai 
PVT  post-LT 
23 Roux loop 
varices 
124 20 0.47 13 12 LT at 1 year of age. PVT 1 year post 
LT. Unsuccessful porto-systemic shunt 
at age 9 years.  Patient was prescribed 
propranolol 0.5mg/kg/day 
Re-listed for LT and started on 4-weekly 
OCT-LAR.  
Reduced GIB episodes for 6 months, 
then GIB stopped. Removed from LT 
list.    
8 
(M) 
 
BA 
failed Kasai 
11 Oesophageal 
varices 
12 2.5 0.33 1 31 LT 4 weeks after OCT-LAR 
administration with no further GIB 
before surgery 
 
9 
(M) 
 
BA 
successful 
Kasai 
23 Roux loop 71 10 0.4 13 12 OCT-LAR started after 6-months severe 
melaena prompting listing for LT. 
Propranolol 0.5mg/kg/day 
No further GIB after the second dose 
and with monthly OCT-LAR injections to 
date. Removed from LT list. 
 
BA: biliary atresia; PVT: portal vein thrombosis; LT: liver transplant; AVM: arterio-venous malformation; KTW: Klippel-Trenaunay-Weber; GIB: gastrointestinal bleeding 
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Table 2 
 
 
TABLE 2.  
EFFECTS OF LONG-ACTING OCTREOTIDE TREATMENT ON BLEEDING EPISODES IN 6 PATIENTS (Patients 2, 3, 4, 6, 
7, 9) 
 
GIB: gastrointestinal bleeding; Data are reported as median (range); Wilcoxon matched pairs test: P <0.05 is statistically 
significant. 
 
 
 
 
 
 Before therapy After therapy P 
Observation period (months)  12   12   
Number of GIB events  22 (12-110) 1.5 (0-27) 0.03 
Hospital admissions for GIB   5.5 (2-7) 0.5 (0-2) 0.03 
Length of hospital stay (days) 47.5  (11-92) 2 (0-42) 0.03 
Required blood units  5 (2-33) 0.5 (0-17) 0.03 
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